Investigational Site Number : 4840001
Guadalajara, Jalisco, Mexico
4 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi84 enrolled69 locationsNCT06500702
Recruiting
Phase 3
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Chronic Rhinosinusitis With Nasal Polyps
Sanofi210 enrolled113 locationsNCT06834360
Recruiting
Phase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyneuropathy
Sanofi160 enrolled115 locationsNCT06290141
Recruiting
Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Asthma
Sanofi1,147 enrolled236 locationsNCT06676319
Recruiting
Phase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Sanofi1,600 enrolled384 locationsNCT06141473
Recruiting
Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Dermatitis Atopic
Sanofi901 enrolled175 locationsNCT05769777
Recruiting
Phase 4
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Asthma
Sanofi1,324 enrolled249 locationsNCT05097287
Recruiting
Phase 3
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
AsthmaWheezing
Sanofi90 enrolled74 locationsNCT06191315
Recruiting
Phase 3
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Pneumococcal Immunization
Sanofi2,320 enrolled134 locationsNCT06824194